Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$21.90 +1.3%	$21.76	$15.47 ▼ $36.37	$749.20M	1.2	232,030 shs	139,751 shs
NLTX Neoleukin Therapeutics	$22.26 +3.9%	$18.51	$2.03 ▼ $14.36	$209.20M	1.11	50,104 shs	201,066 shs
NUVB Nuvation Bio	$2.25 +5.4%	$2.13	$1.54 ▼ $3.97	$763.88M	1.33	3.09 million shs	3.50 million shs
PHAR Pharming Group	$9.95 -1.5%	$10.60	$6.65 ▼ $12.61	$681.67M	0.02	6,084 shs	682 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	-1.14%	+6.35%	-7.09%	+20.78%	+10.14%
NLTX Neoleukin Therapeutics	+3.87%	+14.15%	+12.65%	+95.95%	-47.72%
NUVB Nuvation Bio	-0.88%	+4.15%	+23.77%	+13.56%	-37.94%
PHAR Pharming Group	-2.42%	-0.59%	-7.09%	+24.85%	+15.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	2.2731 of 5 stars	4.6	0.0	0.0	0.0	2.9	0.8	0.0
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	3.1244 of 5 stars	4.6	0.0	0.0	0.0	2.5	4.2	0.0
PHAR Pharming Group	2.08 of 5 stars	3.5	3.0	0.0	0.0	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	79.39% Upside
NLTX Neoleukin Therapeutics	0.00	N/A	N/A	N/A
NUVB Nuvation Bio	3.20	Buy	$7.17	219.23% Upside
PHAR Pharming Group	3.00	Buy	$30.00	201.51% Upside

Current Analyst Ratings Breakdown

Latest NLTX, PHAR, NUVB, and AVBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	AVBP ArriVent BioPharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	$33.00
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/2/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $5.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
4/23/2025	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	$11.08 per share	N/A
NUVB Nuvation Bio	$7.87M	97.06	N/A	N/A	$1.37 per share	1.64
PHAR Pharming Group	$297.20M	2.29	$0.07 per share	139.62	$3.25 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
NLTX Neoleukin Therapeutics	-$57.56M	-$3.11	N/A	∞	N/A	N/A	-37.22%	-30.91%	N/A
NUVB Nuvation Bio	-$567.94M	-$2.35	N/A	N/A	N/A	-5,534.21%	-44.14%	-32.97%	8/4/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.20	N/A	331.67	N/A	-4.14%	-6.01%	-3.23%	7/30/2025 (Estimated)

Latest NLTX, PHAR, NUVB, and AVBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	PHAR Pharming Group	-$0.15	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	N/A	N/A	N/A	$0.42 million	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
NLTX Neoleukin Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.34	14.34
NLTX Neoleukin Therapeutics	N/A	15.33	15.33
NUVB Nuvation Bio	N/A	9.01	9.01
PHAR Pharming Group	0.39	2.76	2.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
NLTX Neoleukin Therapeutics	52.37%
NUVB Nuvation Bio	61.67%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
NLTX Neoleukin Therapeutics	1.58%
NUVB Nuvation Bio	29.93%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
NLTX Neoleukin Therapeutics	90	9.40 million	9.25 million	No Data
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable

NLTX, PHAR, NUVB, and AVBP Headlines

Recent News About These Companies

Pharming Group N.V. (PHGUF) stock price, news, quote & history ...

July 11, 2025 | sg.finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Trading Down 3.5% - Should You Sell?

July 9, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - What's Next?

July 8, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down - What's Next?

July 3, 2025 | marketbeat.com

AS:PHAR Financials | Pharming Group NV - Investing.com

July 2, 2025 | investing.com

Pharming Group (NASDAQ:PHAR) Stock Price Down 4.9% - Here's What Happened

July 1, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Here's Why

June 30, 2025 | marketbeat.com

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve ... - Nasdaq

June 25, 2025 | nasdaq.com

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS ...

June 25, 2025 | morningstar.comM

Pharming Group (NASDAQ:PHAR) Shares Down 3.2% - Here's Why

June 18, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Here's What Happened

June 17, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - Time to Buy?

June 16, 2025 | marketbeat.com

European Penny Stocks Under €200M Market Cap To Watch

June 13, 2025 | uk.finance.yahoo.com

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

June 11, 2025 | finance.yahoo.com

Pharming Group Announces Key Board Appointments and Approvals at 2025 AGM

June 11, 2025 | tipranks.com

Pharming Group to participate in June investor conferences

May 28, 2025 | finance.yahoo.com

Pharming Group to participate in June investor conferences | PHARM Stock News

May 28, 2025 | gurufocus.com

Pharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)

May 10, 2025 | finance.yahoo.com

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Pharming Group N.V. 2025 Q1 - Results - Earnings Call Presentation

May 9, 2025 | seekingalpha.com

Pharming Group’s Strong Financial Performance and Strategic Growth Drive Buy Rating

May 8, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 High-Risk, High-Reward Stocks With Explosive Upside
By Nathan Reiff | July 16, 2025
View 3 High-Risk, High-Reward Stocks With Explosive Upside
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

NLTX, PHAR, NUVB, and AVBP Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$21.90 +0.28 (+1.30%)

Closing price 03:58 PM Eastern

Extended Trading

$21.90 0.00 (0.00%)

As of 04:02 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Neoleukin Therapeutics NASDAQ:NLTX

$22.26 +0.83 (+3.87%)

As of 07/14/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

Nuvation Bio NYSE:NUVB

$2.24 +0.12 (+5.40%)

Closing price 03:59 PM Eastern

Extended Trading

$2.23 -0.02 (-0.67%)

As of 04:10 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Pharming Group NASDAQ:PHAR

$9.95 -0.15 (-1.49%)

Closing price 03:58 PM Eastern

Extended Trading

$9.95 0.00 (0.00%)

As of 04:09 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time